An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of 660 Mg (2 X 330 Mg Tablets) Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 300 Mg Of The Immediate Release Formulation Administered Twice Daily.

Trial Profile

An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of 660 Mg (2 X 330 Mg Tablets) Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 300 Mg Of The Immediate Release Formulation Administered Twice Daily.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2014

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Epilepsy; Neuropathic pain; Pain
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 03 Mar 2011 Actual initiation date (Feb 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top